CABALETTA BIO INC's ticker is CABA and the CUSIP is 12674W109. A total of 61 filers reported holding CABALETTA BIO INC in Q1 2022. The put-call ratio across all filers is 0.03 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $6,971 | +56.1% | 540,000 | 0.0% | 0.32% | +47.5% |
Q1 2023 | $4,466 | -99.9% | 540,000 | 0.0% | 0.22% | -16.7% |
Q4 2022 | $4,995,000 | +1323.1% | 540,000 | 0.0% | 0.26% | +1215.0% |
Q3 2022 | $351,000 | -38.6% | 540,000 | 0.0% | 0.02% | -44.4% |
Q2 2022 | $572,000 | -47.8% | 540,000 | 0.0% | 0.04% | -35.7% |
Q1 2022 | $1,096,000 | -46.5% | 540,000 | 0.0% | 0.06% | -30.0% |
Q4 2021 | $2,047,000 | -89.5% | 540,000 | -66.3% | 0.08% | -88.3% |
Q3 2021 | $19,497,000 | +41.4% | 1,603,361 | 0.0% | 0.68% | +40.1% |
Q2 2021 | $13,789,000 | -22.5% | 1,603,361 | 0.0% | 0.49% | -19.5% |
Q1 2021 | $17,797,000 | -11.1% | 1,603,361 | 0.0% | 0.60% | -6.1% |
Q4 2020 | $20,010,000 | +17.9% | 1,603,361 | +2.4% | 0.64% | +9.5% |
Q3 2020 | $16,979,000 | -2.6% | 1,566,361 | 0.0% | 0.59% | -23.4% |
Q2 2020 | $17,434,000 | +52.5% | 1,566,361 | 0.0% | 0.77% | -1.7% |
Q1 2020 | $11,434,000 | -47.7% | 1,566,361 | 0.0% | 0.78% | -37.1% |
Q4 2019 | $21,882,000 | – | 1,566,361 | – | 1.24% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lynx1 Capital Management LP | 2,106,000 | $32,053,320 | 21.20% |
COMMODORE CAPITAL LP | 2,525,753 | $38,441,961 | 4.49% |
Bain Capital Life Sciences Investors, LLC | 2,000,000 | $30,440,000 | 3.40% |
VR Adviser, LLC | 1,973,253 | $30,032,911 | 3.16% |
Cormorant Asset Management, LP | 2,879,424 | $43,824,833 | 2.56% |
Velan Capital Investment Management LP | 150,000 | $2,283,000 | 1.84% |
Redmile Group, LLC | 1,774,252 | $27,004,115 | 1.28% |
TCG Crossover Management, LLC | 486,795 | $7,409,020 | 1.09% |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,340,118 | $35,616,596 | 0.78% |
Integral Health Asset Management, LLC | 330,000 | $5,022,600 | 0.70% |